GlassScriptPhysician profile
Ashley Smith-Boutin
NPI 1073922464
$1,937.70
in general payments reported to CMS, 2019-2025
16 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,466 · 2022: $274 · 2023: $75.75 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.83 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $339.59 | 2021-2022 | |
| Novo Nordisk INC | $316.08 | 2021-2025 | Wegovy |
| Pfizer INC. | $273.76 | 2021 | |
| Amgen INC. | $142.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $66.26 | 2021 | |
| Amarin Pharma, INC. | $65.37 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.79 | 2021 | |
| Lilly USA, LLC | $41.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.32 | 2022 | |
| Glaxosmithkline, LLC. | $19.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.28 | 2021 | |
| Horizon Therapeutics Plc | $15.48 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Smith-Boutin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.